Cargando…

Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?

PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating LDL cholesterol. There are inconsistent data in some populations concerning the association between PCSK9, LDL and CRP. The emerging importance of the inhibition of PCSK9 for the treatment of hypercholes...

Descripción completa

Detalles Bibliográficos
Autores principales: Mba, Camille Maadjhou, Mbacham, Wilfred, Sobngwi, Eugène, Mbanya, Jean Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946635/
https://www.ncbi.nlm.nih.gov/pubmed/32021342
http://dx.doi.org/10.2147/DMSO.S234243
_version_ 1783485402175242240
author Mba, Camille Maadjhou
Mbacham, Wilfred
Sobngwi, Eugène
Mbanya, Jean Claude
author_facet Mba, Camille Maadjhou
Mbacham, Wilfred
Sobngwi, Eugène
Mbanya, Jean Claude
author_sort Mba, Camille Maadjhou
collection PubMed
description PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating LDL cholesterol. There are inconsistent data in some populations concerning the association between PCSK9, LDL and CRP. The emerging importance of the inhibition of PCSK9 for the treatment of hypercholesterolemia warrants investigations in different populations. The aim of this study from a Sub-Saharan African population was to evaluate the association between PCSK9 and hs-CRP levels and plasma lipid levels in patients with type 2 diabetes (T2D) and obese and lean controls. PATIENTS AND METHODS: A cross-sectional analytical study was conducted in a major hospital in Yaoundé, Cameroon in a cohort of 162 participants (53% females). There were 54 non-obese T2D patients matched for age and sex to 54 obese nondiabetic and 54 nondiabetic lean subjects. PCSK9 level was assessed by sandwich ELISA method and hsCRP by nephelometry. RESULTS: PCSK9 and hs-CRP levels were significantly higher in obese and T2D subjects when compared to lean controls (p<0.001 and p=0.002, respectively). The association between PCSK9 and triglyceride levels in the overall population was gender dependent (p=0.04) and subgroup analysis showed a significant positive correlation between PCSK9 and triglyceride levels in males but not in females (r=0.56, p=0.02 and r=0.2 and p=0.1, respectively). Multilinear regression analysis identified BMI as an independent predictor for PCSK9 levels and this association was maintained after adjustment for confounders; adjusted β-coefficient; 36.1 (95% CI; 29.2–47.4). We did not find an association between PCSK9 and any plasma lipid levels in obese and T2D subjects, nor between PCSK9 and hs-CRP levels. CONCLUSION: Obese and type 2 diabetes subjects have higher PCSK9 levels when compared to lean controls, suggesting that these metabolic states potentially impact PCSK9 levels in Cameroonian patients.
format Online
Article
Text
id pubmed-6946635
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69466352020-02-04 Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes? Mba, Camille Maadjhou Mbacham, Wilfred Sobngwi, Eugène Mbanya, Jean Claude Diabetes Metab Syndr Obes Original Research PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating LDL cholesterol. There are inconsistent data in some populations concerning the association between PCSK9, LDL and CRP. The emerging importance of the inhibition of PCSK9 for the treatment of hypercholesterolemia warrants investigations in different populations. The aim of this study from a Sub-Saharan African population was to evaluate the association between PCSK9 and hs-CRP levels and plasma lipid levels in patients with type 2 diabetes (T2D) and obese and lean controls. PATIENTS AND METHODS: A cross-sectional analytical study was conducted in a major hospital in Yaoundé, Cameroon in a cohort of 162 participants (53% females). There were 54 non-obese T2D patients matched for age and sex to 54 obese nondiabetic and 54 nondiabetic lean subjects. PCSK9 level was assessed by sandwich ELISA method and hsCRP by nephelometry. RESULTS: PCSK9 and hs-CRP levels were significantly higher in obese and T2D subjects when compared to lean controls (p<0.001 and p=0.002, respectively). The association between PCSK9 and triglyceride levels in the overall population was gender dependent (p=0.04) and subgroup analysis showed a significant positive correlation between PCSK9 and triglyceride levels in males but not in females (r=0.56, p=0.02 and r=0.2 and p=0.1, respectively). Multilinear regression analysis identified BMI as an independent predictor for PCSK9 levels and this association was maintained after adjustment for confounders; adjusted β-coefficient; 36.1 (95% CI; 29.2–47.4). We did not find an association between PCSK9 and any plasma lipid levels in obese and T2D subjects, nor between PCSK9 and hs-CRP levels. CONCLUSION: Obese and type 2 diabetes subjects have higher PCSK9 levels when compared to lean controls, suggesting that these metabolic states potentially impact PCSK9 levels in Cameroonian patients. Dove 2019-12-31 /pmc/articles/PMC6946635/ /pubmed/32021342 http://dx.doi.org/10.2147/DMSO.S234243 Text en © 2019 Mba et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mba, Camille Maadjhou
Mbacham, Wilfred
Sobngwi, Eugène
Mbanya, Jean Claude
Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_full Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_fullStr Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_full_unstemmed Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_short Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_sort is pcsk9 associated with plasma lipid levels in a sub-saharan african population of patients with obesity and type 2 diabetes?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946635/
https://www.ncbi.nlm.nih.gov/pubmed/32021342
http://dx.doi.org/10.2147/DMSO.S234243
work_keys_str_mv AT mbacamillemaadjhou ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes
AT mbachamwilfred ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes
AT sobngwieugene ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes
AT mbanyajeanclaude ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes